InflaRx announces ordinary shares and warrants offering, no amount given

InflaRx (IFRX) N.V. announced that it has commenced an underwritten public offering of ordinary shares of the company, and in lieu of ordinary shares to certain investors, pre-funded warrants to purchase the company’s ordinary shares. The company intends to use the net proceeds from the offering primarily to fund clinical development of its pipeline candidates, including vilobelimab and INF904, and for general corporate purposes. Guggenheim Securities is serving as book-running manager for the proposed offering.